Skip to main content

Table 1 Histological assessments of new bone area in the marrow of a rabbit femur

From: Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

 

Group 1 (Control)

Group 2 (rh-BMP-2)

Group 3 (ZOL)

Group 4 (rh-BMP-2 + ZOL)

p value

Haematoxylin and eosin (%, n = 9)

 3 weeks after implantation

40.0(33.1 to 42.9)

56.9(40.9 to 66.9)

11.0(8.2 to 13.4)

57.9(40.2 to 68.6)

<0.001

 6 weeks after implantation

13.9(11.1 to 18.0)

13.4(9.9 to 16.9)

12.3(9.9 to 15.6)

39.0(32.0 to 47.0)

<0.001

Masson’s trichrome (%, n = 9)

 3 weeks after implantation

36.5(25.4 to 40.9)

51.0(37.6 to 59.4)

13.5(10.7 to 19.9)

40.9(31.0 to 63.1)

<0.001

 6 weeks after implantation

12.0(9.5 to 14.4)

11.9(6.9 to 15.5)

12.3(9.5 to 14.4)

30.0(24.3 to 30.1)

<0.001

  1. Variables present percentages of new bone areas in tissues as median, minimum, and maximum. P values indicate the statistical differences between the groups. Note: β-TCP Beta-tricalcium phosphate, rh-BMP-2 Recombinant human bone morphogenetic protein-2, ZOL Zoledronate.